Indolealkylamines

Biotransformations and potential drug-drug interactions

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs, studies on their biotransformations and pharmacokinetics would facilitate the understanding and prevention of unwanted drug-drug interactions (DDIs). A stable, principal metabolite of an IAA drug of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and β-carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs. Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential DDIs of these therapeutic and abused IAA drugs are described.

Original languageEnglish (US)
Pages (from-to)242-253
Number of pages12
JournalAAPS Journal
Volume10
Issue number2
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Biotransformation
Drug Interactions
Street Drugs
Serotonin
Cytochrome P-450 CYP2D6
Pharmaceutical Preparations
Tryptamines
Carbolines
Pharmacokinetics
Biomarkers
Therapeutics

Keywords

  • CYP2D6
  • Drug interactions
  • Indolealkylamine
  • MAO
  • Metabolism
  • Pharmacogenetics
  • Tryptamine

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Indolealkylamines : Biotransformations and potential drug-drug interactions. / Yu, Aiming.

In: AAPS Journal, Vol. 10, No. 2, 06.2008, p. 242-253.

Research output: Contribution to journalArticle

@article{3cc9735b574d488da1b8c8c6413b825e,
title = "Indolealkylamines: Biotransformations and potential drug-drug interactions",
abstract = "Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs, studies on their biotransformations and pharmacokinetics would facilitate the understanding and prevention of unwanted drug-drug interactions (DDIs). A stable, principal metabolite of an IAA drug of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and β-carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs. Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential DDIs of these therapeutic and abused IAA drugs are described.",
keywords = "CYP2D6, Drug interactions, Indolealkylamine, MAO, Metabolism, Pharmacogenetics, Tryptamine",
author = "Aiming Yu",
year = "2008",
month = "6",
doi = "10.1208/s12248-008-9028-5",
language = "English (US)",
volume = "10",
pages = "242--253",
journal = "AAPS Journal",
issn = "1550-7416",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Indolealkylamines

T2 - Biotransformations and potential drug-drug interactions

AU - Yu, Aiming

PY - 2008/6

Y1 - 2008/6

N2 - Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs, studies on their biotransformations and pharmacokinetics would facilitate the understanding and prevention of unwanted drug-drug interactions (DDIs). A stable, principal metabolite of an IAA drug of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and β-carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs. Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential DDIs of these therapeutic and abused IAA drugs are described.

AB - Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs, studies on their biotransformations and pharmacokinetics would facilitate the understanding and prevention of unwanted drug-drug interactions (DDIs). A stable, principal metabolite of an IAA drug of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and β-carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs. Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential DDIs of these therapeutic and abused IAA drugs are described.

KW - CYP2D6

KW - Drug interactions

KW - Indolealkylamine

KW - MAO

KW - Metabolism

KW - Pharmacogenetics

KW - Tryptamine

UR - http://www.scopus.com/inward/record.url?scp=53849113961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849113961&partnerID=8YFLogxK

U2 - 10.1208/s12248-008-9028-5

DO - 10.1208/s12248-008-9028-5

M3 - Article

VL - 10

SP - 242

EP - 253

JO - AAPS Journal

JF - AAPS Journal

SN - 1550-7416

IS - 2

ER -